IQVIA Holdings Stock Reaches 52-Week High at $271.82

IQVIA Holdings Inc., a leader in life sciences data and analytics, reached a 52-week high of $271.82 per share on September 15, 2026, following robust second-quarter financial results and positive analyst sentiment. The stock has surged by 45.17% over the past year and 61% in the prior six months, reflecting growing confidence in its market position within the life sciences tools and services sector, which has a market capitalization of $44.6 billion. The company reported adjusted diluted earnings per share (EPS) of $3.15, exceeding the $3.04 forecast, alongside $4.37 billion in revenue, slightly above the anticipated $4.30 billion estimate. These results have contributed to upward revisions in analyst price targets, with Stifel raising its estimate to $276 from $220 while maintaining a Buy rating, and Truist Securities increasing its target to $300 from $245, citing strong second-quarter bookings and an AI-driven strategy as key drivers. Eleven analysts have revised their earnings estimates upward since the last reporting period. Additionally, IQVIA recently issued a $2 billion senior notes offering at a 6.375% annual interest rate, maturing in 2034. According to InvestingPro’s valuation analysis, the stock trades above its fair value, placing it on the platform’s list of most overvalued shares. The company’s performance underscores its expanding role in the digital transformation of healthcare data and analytics, positioning it well amid rising demand for precision medicine and AI-driven diagnostics.